PTM Wealth Management LLC Takes $256,000 Position in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• PTM Wealth Management LLC recently acquired a new stake in NewAmsterdam Pharma Company N.V., investing approximately $256,000 for 12,900 shares.
• Insider Johannes Jacob Piete Kastelein sold 50,000 shares for about $1.21 million, marking a significant reduction in ownership.
• Analysts give NewAmsterdam Pharma a consensus rating of "Moderate Buy", with a price target averaging $41.55, despite the company reporting a net margin of -259.07%.

PTM Wealth Management LLC acquired a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 12,900 shares of the company's stock, valued at approximately $256,000.

Other large investors also recently added to or reduced their stakes in the company. Quarry LP purchased a new position in NewAmsterdam Pharma in the 1st quarter worth approximately $25,000. GF Fund Management CO. LTD. purchased a new position in NewAmsterdam Pharma in the 4th quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after purchasing an additional 596 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in NewAmsterdam Pharma by 130.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after purchasing an additional 3,390 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in shares of NewAmsterdam Pharma during the 1st quarter worth approximately $127,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the business's stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total transaction of $1,214,500.00. Following the transaction, the insider owned 119,302 shares of the company's stock, valued at approximately $2,897,845.58. The trade was a 29.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director James N. Topper acquired 1,260 shares of the stock in a transaction on Monday, September 8th. The shares were bought at an average cost of $24.99 per share, for a total transaction of $31,487.40. Following the purchase, the director directly owned 3,027,864 shares of the company's stock, valued at $75,666,321.36. The trade was a 0.04% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders bought 5,511 shares of company stock valued at $112,233 and sold 324,954 shares valued at $7,844,906. Insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $24.19 on Monday. The stock has a market capitalization of $2.72 billion, a PE ratio of -14.93 and a beta of -0.01. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $27.35. The business has a 50 day simple moving average of $23.67 and a 200-day simple moving average of $20.82.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. The business had revenue of $19.15 million during the quarter, compared to analysts' expectations of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. On average, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on NAMS shares. Needham & Company LLC reaffirmed a "buy" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Citigroup started coverage on NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a "buy" rating and a $42.00 price target on the stock. Stifel Nicolaus assumed coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.55.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.